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Abstract Oral lichen planus (OLP) is a chronic, immunologically mediated disease, defined by 
periods of exacerbation and quiescence. The disease is associated with a low mortality 
risk, but in some instances, morbidity can be important, especially in extensive, erosive 
forms, with a significant impact on the quality of life.  
OLP is a chronic T-cell mediated inflammatory disease involving the oral cavity, the 
most common lesions being located on the oral mucosa, tongue and gums. Its etiology 
remains in part unknown, but several factors proved to be involved in the development of 
the disease (drugs, dental materials, infectious agents, psychological factors, 
autoimmunity and genetic predisposition). 
The therapeutic approach should take into account the type of lesion and the extent of 
the disease, as well as the possible adverse effects. Although several therapies are 
available, OLP treatment still remains a challenge. Photodynamic therapy (PDT) is 
widely used in dermatology, finding applicability in the treatment of an increasing 
number of conditions. Recent research has shown the role of PDT in the treatment of 
OLP. It is a minimally invasive therapy with few side effects and promising results.   
Keywords  oral lichen planus, photosensitizer, therapy 
Highlights  The therapeutic approach in the OLP remains a challenge; although many therapies are 
available, none of them can still be considered the ideal therapeutic approach. 
 PDT seems to be a promising therapy, but with heterogeneous results due to lack of 
standardization (the available studies using different sources of light, wavelengths and 
photosensitizers). 
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Introduction 
Oral lichen planus (OLP) affects 0.5-2% of the general 
population (1). OLP is a chronic T-cell mediated 
inflammatory disease involving the oral cavity, the most 
common lesions being located on the oral mucosa, tongue 
and gums. Its etiology remains unknown, but several 
factors proved to be involved in the development of the 
disease including drugs, dental materials, infectious 
agents, psychological factors, autoimmunity and genetic 
predisposition (2-5). There are numerous studies attesting 
the role of hepatitis C virus infection in the pathogenesis 
of OLP; the presence of viral RNA was revealed in the 
samples from the oral mucosa of OLP patients (6). It 
seems that lymphocytes, the main cells involved in the 
pathogenesis of OLP, are activated under the action of an 
internal or external factor, which will lead to the release 
of high amounts of mediators of inflammation, resulting 
in the apoptosis of keratinocytes (7-9). 
 From a clinical point of view, several forms of OLP 
have been described, namely reticular, papular, plaque-
like, atrophic, bullous and erosive. The atrophic, erosive 
and bullous forms associate pain as the main symptom, 
which is often a therapeutic challenge (10). Several 
therapies are available, but none is curative. The most 
important objective of the therapy should be the reduction 
of the inflammatory process and consequently, the 
alleviation of pain (11). Topical corticosteroids (with 
moderate or high potency) are the first-line treatment in 
OLP, systemic corticosteroids being recommended only 
in severe or non-responsive cases to topical therapy as 
well as in cases when the patient associates cutaneous 
lesions (12). The most important side effect of local 
steroid therapy is oral candidiasis; therefore, it is often 
recommended to associate corticosteroids with an 
antifungal drug. The atrophy of the oral mucosa has rarely 
been reported (11).  
In chronic cases, when corticosteroids are used for 
long periods of time, although the level of absorption is 
low, there is a risk of adrenal suppression; therefore, these 
patients should be carefully monitored (13). Other topical 
therapeutic options are calcineurin inhibitors and 
retinoids. Immunosuppressant drugs including 
methotrexate, cyclosporine and azathioprine have also 
been used (1, 13). Since OLP lesions resistant to 
corticosteroids have been reported, it is necessary to use 
other therapies. In this context, several authors have 
studied the efficacy of photodynamic therapy (PDT) in 
OLP treatment. It seems that PDT is effective in the 
treatment of OLP by inducing the apoptosis of 
inflammatory cells, which are the most important players 
in OLP pathogenesis (14). 
Discussions 
The psychological impact of oral lichen planus on 
the patient’s life quality  
Disorders of the oral cavity are associated with a 
significant impact on the patient’s life quality. Fadler et 
al. conducted a study on 149 patients and evaluated the 
psychological impact of oral mucosal disorders. They 
found that bullous diseases of the oral mucosa and OLP 
had had the greatest impact (15). Radwan-Oczko et al. 
analyzed 42 OLP patients with a mean duration of the 
disease of 43 months. Several questionnaires were used in 
order to assess the impact of OLP on the patients’ life 
quality. There was a positive correlation between the 
duration of the disease and the level of perceived stress 
and a negative correlation between the duration of the 
disease and the quality of life (16). 
Lopez-Jornet et al. demonstrated that psychological 
discomfort and social disability are increased in OLP 
patients (17). Another recent study showed that 
psychiatric disorders such as anxiety and depression are 
more common among these patients (18). Moreover, 
Karbach et al. compared OLP patients with those with 
oral cancer and identified a higher pain score of the 
lesions and a lower social disability score among OLP 
patients (19). A study revealed that the degree of stress is 
higher among patients with erosive OLP than among 
those with non-erosive OLP (20). Interestingly enough, a 
case control study evaluated the psychological profile of 
OLP patients and highlighted that low self-control and 
depression are more strongly associated with mild forms 
of OLP (reticular and papular) than with severe forms. 
This might have a role in the progression of OLP lesions 
(21). 
Stress seems to contribute to the development of OLP 
lesions (22). It has been suggested that the oral mucosa 
has increased reactivity to psychological stimuli (23). 
Stress, both acute and chronic, induces changes in the 
immune response. However, it should be taken into 
account that the disorder itself is a stressful factor for the 
patient (24).  
Photodynamic therapy – a promising therapy 
Photodynamic therapy is a therapeutic approach that is 
increasingly used in a broad spectrum of disorders. In 
dermatology, there are various diseases that may benefit 
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from this therapy (25-27). In 1900, the medical student 
Oscar Raab and his professor Von Tappeiner described 
PDT as an antimicrobial therapy, observing Paramecium's 
photoinhibition. They noticed that acridine, which is 
chemically inert under dark conditions, is activated by 
sunlight leading to the destruction of the Paramecium 
species (28, 29). In 1999, the FDA approved PDT in the 
treatment of precancerous lesions of the face and scalp (30-
32). PDT has the advantage of being a minimally invasive 
technique that preserves the normal tissue (33, 34). 
PDT can be regarded as a particular form of 
photochemotherapy, based on a photochemical reaction, 
which uses a photosensitizer, a source of light and 
oxygen, exerting a selective cytotoxic effect (35, 36). The 
activation of the photosensitizer by light results in the 
generation of reactive oxygen species, especially singlet 
oxygen, leading to tissue necrosis and apoptosis (37, 38). 
The main steps of the technique include the 
administration of the photosensitizing agent, which will 
accumulate selectively in the target cells, followed by the 
illumination of the respective area with a light source. 
Numerous light sources are employed in PDT, including 
coherent and non-coherent light sources. The main 
sources that can be used are ultraviolet light (330-400 
nm), red light (600-700 nm) and near infrared light (700-
100 nm). Longer wavelength light penetrates deeper into 
the tissue (33). Most of the photosensitizers are activated 
at a wavelength between 630-700 nm (39).  
A series of photosensitizers have been used in time, 
initially systemically and then topically. Nowadays, 5-
aminolevulinic acid (ALA) remains one of the most used 
topical agents. ALA is endogenously converted into 
protoporphyrin IX, a photosensitizing molecule, which 
leads to the formation of reactive oxygen species after 
exposure to an appropriate wavelength (400-410 nm, 635 
nm) (40). Besides ALA, one of the most used agents is its 
derivative, methyl aminolevulinate (MAL) (41). Other 
photosensitizers are phenothiazines such as toluidine blue 
and methylene blue (620-700 nm) that are especially used 
in dentistry (39). 
In most cases, PDT is well tolerated, the main side 
effects being pain, erythema and, in some cases, urticaria. 
Scar formation or other allergic reactions may occur less 
frequently (42, 43). 
The role of photodynamic therapy in oral lichen planus 
The results of the studies on PDT efficacy in the 
treatment of OLP, are heterogeneous. This can be 
explained by the fact that different photosensitizers (ALA, 
methylene blue, toluidine blue, etc.) and various light 
sources (diode laser, light emitting diode) are employed 
(44). Grandi et al. reviewed the data on the efficacy of 
PDT in OLP therapy. They analyzed one case series, three 
prospective single-arm and five open-label randomized 
clinical trials and noticed that a wide range of 
photosensitizers and different modalities to evaluate the 
patients were used. The analysis concluded that beneficial 
effects of PDT were observed in all studies, but the 
overall response rate varied between 0 and 29%. There 
were no notable side effects during the treatment. Grandi 
et al. draw attention to the fact that the effects of PDT 
might increase weeks or months after application, thus the 
follow-up period is very important and could have 
repercussions on the outcomes of the studies (45). 
A systematic review by Akram et al. on the role of 
PDT in OLP treatment showed that none of the analyzed 
studies evaluated histopathological changes after PDT. In 
addition, the authors pointed out that the assessment of 
PDT efficacy is difficult given that there is no consensus 
on the parameters which should be used and in most 
studies the follow-up period was too short. Furthermore, 
they emphasized the need to compare the results with a 
control group consisting of patients treated with 
corticosteroids (46). 
The meta-analysis by Jajarm et al. focused on 
comparing the effectiveness of corticosteroid therapy with 
new phototherapy methods including low-level laser 
therapy and PDT. They observed that low-level laser 
therapy is effective in relieving pain and clinical signs. 
However, there were no differences when these two 
parameters were analyzed in comparison with the results 
obtained in patients treated with corticosteroids. Low-
level laser therapy was superior to corticosteroids only 
when the effect on the severity of lesions was evaluated. 
With respect to the reduction in size of OLP lesions, 
similar results were obtained when PDT was compared 
with corticosteroids (47). 
Methylene blue-mediated PDT   
Methylene blue is an agent that has been used in 
medicine for over 100 years. It is used in various diseases 
such as methemoglobinemia or urolithiasis; the compound 
has low toxicity on human tissue. It is best absorbed at 
wavelengths higher than 620 nm (48). Aghahosseini et al. 
evaluated the efficacy of PDT in OLP in a study that 
included 26 lesions from 13 patients with 
histopathologically confirmed OLP, refractory to previous 
treatments, including topical application of corticosteroids 
or cyclosporine. They used 5% methylene blue as a 
photosensitizer and the irradiation was performed using 
light laser with a wavelength of 632 nm. An improvement 
was obtained for 16 lesions. The mean reduction in lesion 
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size was 44.3% at 12 weeks after the therapy. Favorable 
results have also been obtained regarding the pain level 
(49). Another recent study using methylene blue as a 
photosensitizer and a light source with a wavelength of 
630 nm included 20 OLP patients. After 4 sessions, 10 
patients experienced a moderate improvement and the rest 
of the patients were unresponsive. Moreover, they 
evaluated the patients two weeks after therapy and 
observed that the lesions significantly improved in 5 
patients, 12 underwent moderate improvement and 3 were 
unresponsive. The results were significantly better four 
weeks after the therapy, a fact which indicated that the 
PDT effect should also be quantified during follow-up 
visits (50). 
Bakhtiari et al. evaluated the efficacy of methylene 
blue-mediated PDT in comparison with topical steroid 
therapy in 30 patients diagnosed with erosive or reticular 
OLP. In the corticosteroid group, 0.5 mg dexamethasone 
solution was used in 5cc water. They showed that PDT is 
as effective as the dexamethasone solution in the OLP 
treatment (51). Mostafa et al. also compared the efficacy 
of methylene blue-mediated PDT with corticosteroids in 
patients with erosive OLP. They included 10 OLP 
patients treated with topical corticosteroids and 10 OLP 
patients treated with PDT in the study (the light source 
used was 630 nm diode laser). In patients treated with 
PDT, a greater reduction in the pain level and lesion size 
was observed when compared to the corticosteroid group. 
Therefore, the authors concluded that PDT is more 
effective than steroid therapy, having the role of reducing 
pain, thus alleviating a symptom (52). Regarding the 
efficacy of topical corticosteroids versus laser 
phototherapy, Akram performed a systematic review in 
order to determine whether the efficacy of low-level laser 
therapy is higher compared to topical corticosteroids in 
OLP patients. Five studies were included, in 3 of them 
topical corticosteroids were superior to low-level laser 
therapy, one study revealed greater improvement using 
low-level laser therapy and one showed similar results 
between the studied groups. These heterogeneous results 
denote that further studies are needed (53).  
ALA-mediated PDT 
ALA interacts with the light source and leads to the 
release of reactive oxygen species (54, 55). It is a second-
generation photosensitizer, synthesized in the laboratory, 
acting as a prodrug, with a good specificity for tumor 
tissue (56). 
A recent study used ALA to assess the efficacy of 
PDT in the treatment of OLP. The complete resolution of 
lesions was achieved in 50% of cases and a partial 
response in 35.7% of them. The symptoms (pain, 
discomfort during speech) disappeared in all patients (57). 
The study conducted by Sulewska et al., which included 
50 patients with reticular OLP, evaluated 5% ALA PDT 
(the illumination source was represented by a diode lamp 
with a high-power LED emitting light at 630 nm), over a 
period of 10 weeks, one session per week. Out of the 124 
lesions, 46 were completely healed. At the end of the 
therapy, the mean reduction in size of the lesions was 
62.91%, and after 12 months, 78.7% respectively (58). 
Rakesh et al. highlighted the utility of PDT in the case of 
10 patients with relapsing erosive OLP. They used 4% 
ALA and red light (wavelength of 600-670 nm). Gingival 
lesions had the poorest response (59).    
PDT was employed in the treatment of premalignant 
oral lesions (60). Thus, the study conducted by Maloth 
included 13 patients with oral leukoplakia and 8 patients 
with OLP. Regarding oral leukoplakia, PDT led to lesion 
resolution in 16.6% of patients and 66.6% of them 
observed partial resolution, the rest of the patients did not 
respond to therapy. In the case of OLP patients, 80% had 
a partial response and 20% had no response. They used 
ALA and blue light with a wavelength of 420 nm. The 
study also compared PDT with conventional therapy, and 
better results were achieved when PDT was used in 
patients with oral leukoplakia; however, in the case of 
OLP the results were similar (61). A systematic review 
evaluated the available data on the efficacy of PDT in 
premalignant lesions, including leukoplakia, 
erythroplakia, erythro-leukoplakia and verrucous 
hyperplasia. Thirteen trials were analyzed and the number 
of the studied patients ranged from 5 to 147. The 
complete response to PDT varied between 27% and 
100%. No response to PDT was recorded in 0 - 25% of 
cases (62).  
Kvaal et al. studied the efficacy of MAL-PDT (red 
light at a wavelength of 600 to 660 nm) on 17 patients 
with OLP. One side of the mouth was treated with MAL-
PDT and the other side was considered the control side. 
The improvement of the lesions was achieved after a 
single session and there was a long-term effect, the 
patients being followed-up for 4 years (63). 
Other photosensitizers 
Jajarm et al. analyzed the efficacy of PDT using 
toluidine blue as a photosensitizer in comparison with 
topical corticosteroids in OLP patients, with the erosive-
atrophic form. No significant differences were found 
when the sign scores of changes were compared between 
the two groups. However, better results have been 
obtained regarding the improvement of the symptoms and 
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efficacy indices in the patients treated with 
corticosteroids. Additionally, the rate of relapse was 
lower among these patients (64). The study by Mirza 
analyzed toluidine blue-mediated PDT, using GaAlAs 
laser with 630 nm wavelength and low-level laser 
therapy, using diode laser with wavelength of 630 nm in 
comparison with conventional corticosteroid therapy in 
patients with OLP. A total of 45 patients were divided 
into 3 groups. Group 1 was treated with toluidine blue-
mediated PDT, group 2 with low-level laser therapy and 
group 3 performed 5-minute rinses with dexamethasone. 
The results highlighted the favorable effects of PDT and 
laser therapy, but corticosteroids were more effective on 
pain relief. The authors concluded that corticosteroids 
remain the gold standard in OLP therapy (65). 
Sobaniec et al. used chlorine e6 (Photolon®) 
consisting of 20% chlorine e6 and 10% dimethyl 
sulfoxide, as a photosensitizer, and a semiconductor laser 
with a wavelength of 660 nm. The patients underwent 10 
sessions at a 2-week interval. Among the 23 patients, 48 
lesions were identified and treated. The mean reduction in 
lesion size was 55% and 14 lesions were completely 
healed. Better results were obtained for lesions localized 
on the cheeks and lips, compared to those on the tongue 
and gums (66).  
Conclusions 
The therapeutic approach in OLP still remains a 
challenge. Although several therapies are available, none 
of them can be considered the ideal therapeutic approach. 
PDT seems to be a promising therapy; however, the 
results are heterogeneous. This is the result of a lack of 
standardization, the available studies using different 
sources of light, wavelengths and photosensitizers. 
Further studies are needed to determine which parameters 
are optimal in order to achieve the best results.  
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